Related Experiment Videos
Short-Term Intraocular Pressure Changes After Intravitreal Aflibercept 8 mg via Prefilled Syringe
Arianna Peyla1, Matteo Bonanata2, Martina Pache2
1Department of Ophthalmology, Ospedale Regionale Di Lugano, Institute of Clinical Neurosciences of Southern Switzerland, Via Pietro Capelli 1, 6962, Lugano, Switzerland. arianna.peyla@eoc.ch.
Ophthalmology and Therapy
|July 17, 2026
Summary
Intravitreal aflibercept 8 mg via prefilled syringe causes a temporary increase in intraocular pressure (IOP) after injection. This IOP rise resolves within 15 minutes and is comparable to other aflibercept formulations.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacology
Background:
- Intravitreal anti-VEGF therapy is standard for nAMD and DMO.
- Transient intraocular pressure (IOP) rise post-injection is known.
- Short-term IOP data for aflibercept 8 mg prefilled syringe (PFS) is limited.
Purpose of the Study:
- Assess short-term IOP changes after intravitreal aflibercept 8 mg PFS.
- Compare IOP changes with aflibercept 8 mg standard syringe and aflibercept 2 mg PFS.
Main Methods:
- Single-center comparative observational cohort study.
- Prospective cohort: aflibercept 8 mg PFS.
- Retrospective cohorts: aflibercept 8 mg standard syringe, aflibercept 2 mg PFS.
- IOP measured using iCare IC200 at baseline, 30s, 5min, 15min.
- Exclusion of patients with glaucoma or ocular hypertension.
Main Results:
- 46 eyes treated with aflibercept 8 mg PFS analyzed.
- No significant baseline IOP differences between groups.
- Aflibercept 8 mg PFS showed significant IOP rise at 30s (mean 51.29 mmHg), decreasing by 15min (mean 20.25 mmHg).
- No statistically significant between-group IOP differences at any timepoint.
Conclusions:
- Intravitreal aflibercept 8 mg PFS causes a transient IOP spike post-injection.
- IOP elevation resolves within 15 minutes.
- IOP response is similar to aflibercept 2 mg PFS and aflibercept 8 mg standard syringe.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...